Johnson & Johnson has agreed to a $5.5 billion settlement to resolve a significant number of lawsuits alleging that its talc products contained asbestos and caused cancer. While the company continues to maintain that its talc products are safe and free of asbestos, the resolution marks a major step in concluding long-running litigation that has persisted for years.
Erik Haas, the company’s vice-president of litigation, stated that while Johnson & Johnson remains confident it would have prevailed in further trials—citing a majority of previous court successes—the settlement is a strategic move to secure closure. According to Haas, the agreement allows the New Jersey-based corporation to focus on its primary mission of developing lifesaving medicines and devices. The company has consistently denied that its products caused illness.
Chris Seeger, a legal representative for approximately 2,500 claimants, noted that the total payout could eventually exceed $7 billion. He emphasized that the agreement assigns specific values to qualifying ovarian cancer claims without capping the total amount Johnson & Johnson might pay. Seeger described the deal as a fair outcome that would satisfy his clients.
The settlement follows a period of legal momentum for the company, which recently achieved several court victories, including the disqualification of certain plaintiffs' lawyers and successful challenges against expert testimony. Notably, a federal judge recently expressed skepticism regarding the ability of plaintiffs to prove that talc was the specific cause of their ovarian cancer.
This new agreement differs from previous attempts to resolve the litigation. Unlike the failed “Texas two-step” bankruptcy strategy—which involved three separate bankruptcy filings by a shell-company subsidiary that were ultimately dismissed—this settlement applies strictly to existing claims rather than future ones. By excluding future lawsuits, the current deal provides more immediate compensation to present plaintiffs, with all payments expected to be distributed within 18 months rather than over a decade.
Johnson & Johnson discontinued the sale of talc-based baby powder in the United States in 2020, replacing it with a cornstarch-based alternative. Prior to the recent settlement, the company faced a mixed legal record, including a multibillion-dollar verdict in favor of 22 women who alleged the powder caused their ovarian cancer, alongside various outright trial wins and reduced verdicts on appeal.
